Myriad Genetics Q3 net loss widens 60% year over year to $43.9 million; Q3 revenue falls year over year to $202.7 million

By Public Technologies21:34 (UTC), 4 November 2026 Updated

Myriad Genetics’ third-quarter 2026 net loss widened 60% year-over-year to $43.9 million.
Revenue fell year-over-year to $202.7 million, while operating expenses rose 6% to $177.6 million.
Agreed to sell Prenatal Health to Labcorp for $210 million plus inventory value, with closing expected by early 2027.
Raised the midpoint of full-year 2026 revenue guidance to a range of $780 million to $790 million, reflecting quarterly results and current trends.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870515) on November 04, 2026, and is solely responsible for the information contained therein.